Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2025 Sep 02
HIV resistance to dolutegravir varies with co-administered agents.
ABSTRACT
We hypothesized that HIV-dolutegravir-resistance is more frequent when co-administered with nucleos(t)ides with shorter intracellular half-lives. Multivariable analysis of 183 viremic (≥200c/mL) participants from four cohorts (N=660 participants) found dolutegravir-resistance in 21 (11.5%). Dolutegravir-resistance was greater with dolutegravir+lamivudine+zidovudine/(one on stavudine) (OR=19.4, 95%CI 5.1-74.3) or dolutegravir+lamivudine+abacavir (OR=5.4, 95%CI 1.1-25.8), compared to dolutegravir+lamivudine+tenofovir.
Related Questions
Beck et al., PMID 40898778
New answer by at Wake Forest Baptist Medical Center (September 10, 2025)
The data are strong to support DTG/lamivudine as a stand-alone regimen with low risk of resistance development as long as patients remain adherent, so there isn't necessarily ...